Banner for leaf pages 2

Exenatide (Byetta)

Also known as Byetta

Exenatide (INN, marketed as Byetta, Bydureon) is a glucagon-like peptide-1 agonist (GLP-1 agonist) medication approved in April 2005 for the treatment of diabetes mellitus type 2. It belongs to the group of incretin mimetics and is manufactured by Amylin Pharmaceuticals. Exenatide in its Byetta form is administered as a subcutaneous injection (under the skin) of the abdomen, thigh, or arm, any time within the 60 minutes before the first and last meal of the day. A once-weekly injection has been approved as of January 27, 2012 under the trademark Bydureon.

Source: Wikipedia

Estimated Total Cost: $239.73 for an average of 28 days supply

What is it prescribed for?

Patients are most commonly prescribed exenatide to treat diabetes, hyperlipidemia, diabetic peripheral neuropathy, and metabolic disorder.

What drug interactions are known?

Do not take exenatide if you are taking any of the following:

Critical Interactions


Significant Interactions

What side effects are related?

Patients taking exenatide most commonly experience side effects like nausea, diarrhea, and headache.

Ajax-loader Loading...